Analysts Anticipate Aeglea Bio Therapeutics Inc (AGLE) to Announce ($0.54) EPS

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has earned an average broker rating score of 1.33 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. Aeglea Bio Therapeutics’ rating score has declined by 33% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Brokerages have set a twelve-month consensus price target of $18.00 for the company and are expecting that the company will post ($0.54) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aeglea Bio Therapeutics an industry rank of 192 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

A number of brokerages have issued reports on AGLE. BMO Capital Markets reissued an “outperform” rating and set a $18.00 price objective on shares of Aeglea Bio Therapeutics in a research report on Wednesday, March 14th. Needham & Company LLC boosted their price objective on shares of Aeglea Bio Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, March 14th. Finally, Zacks Investment Research downgraded shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th.

Shares of Aeglea Bio Therapeutics stock traded down $0.13 during trading on Friday, reaching $10.37. 58,425 shares of the company’s stock were exchanged, compared to its average volume of 92,521. The stock has a market cap of $181.37, a P/E ratio of -5.76 and a beta of 1.38. Aeglea Bio Therapeutics has a fifty-two week low of $2.81 and a fifty-two week high of $11.35.

A number of institutional investors have recently modified their holdings of the business. Jennison Associates LLC grew its position in shares of Aeglea Bio Therapeutics by 0.6% in the 4th quarter. Jennison Associates LLC now owns 1,393,439 shares of the biotechnology company’s stock worth $7,539,000 after buying an additional 8,372 shares during the period. Vanguard Group Inc. grew its position in shares of Aeglea Bio Therapeutics by 9.4% in the 2nd quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after buying an additional 12,966 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Aeglea Bio Therapeutics by 150.8% in the 4th quarter. Renaissance Technologies LLC now owns 32,100 shares of the biotechnology company’s stock worth $174,000 after buying an additional 19,300 shares during the period. 47.43% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Analysts Anticipate Aeglea Bio Therapeutics Inc (AGLE) to Announce ($0.54) EPS” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3293882/analysts-anticipate-aeglea-bio-therapeutics-inc-agle-to-announce-0-54-eps.html.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Atlantic Capital  Receiving Somewhat Favorable Press Coverage, Accern Reports
Atlantic Capital Receiving Somewhat Favorable Press Coverage, Accern Reports
Foresight Energy  Receives Daily Media Sentiment Rating of -0.02
Foresight Energy Receives Daily Media Sentiment Rating of -0.02
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Park-Ohio  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Park-Ohio Stock Price
Ribbon Communications Inc  Receives $7.56 Consensus PT from Analysts
Ribbon Communications Inc Receives $7.56 Consensus PT from Analysts
Analysts Set Progressive Co.  Price Target at $53.43
Analysts Set Progressive Co. Price Target at $53.43
Brokerages Set Fortune Brands Home & Security  Target Price at $73.62
Brokerages Set Fortune Brands Home & Security Target Price at $73.62


© 2006-2018 Ticker Report. Google+.